Rimegepant (Nurtec ODT) Daily vs Every Other Day for Migraine Prevention: What a 692-Person Trial Found
In a 692-person trial, rimegepant (Nurtec ODT) taken once daily cut 1.8 more monthly migraine days than placebo, while the approved every-other-day schedule cut 0.6 more.
On this pageJump to a section8
Why This Study Was Done
Rimegepant (Nurtec ODT) is a gepant, a small-molecule drug that blocks the CGRP receptor. It is unusual because it is approved for two jobs: stopping a migraine attack once it starts, and preventing attacks when taken on a schedule. In the US, the approved preventive schedule is 75 mg every other day. If you want background on the molecule itself, our explainer on how CGRP drives an attack and how the newer drugs block it covers it.
The every-other-day schedule came from an earlier phase 2/3 trial in which rimegepant lowered monthly migraine days by 4.3 compared with 3.5 on placebo in weeks 9 to 12, a gap of about 0.8 days. That gap was modest, and it left an open question: would taking the same tablet every day do more?
This new trial, published in Neurology, tested both schedules against placebo in the same study.
What the Researchers Did
This was a phase 4, double-blind, randomized controlled trial run at outpatient and research sites in 10 countries. Adults had at least a one-year history of episodic migraine, with or without aura, and 4 to 14 migraine attacks a month.
Everyone first completed a 28-day observation period to set their baseline. They were then randomly assigned to one of three groups for 12 weeks:
- Rimegepant 75 mg once daily (229 people)
- Rimegepant 75 mg every other day, with a placebo tablet on the days in between (232 people)
- Placebo once daily (231 people)
In total, 692 people were treated. The median age was 44, and 86.7% were women.
The primary outcome was the drop in monthly migraine days from the observation period, averaged over the full 12 weeks. The results are reported as the difference between each rimegepant group and placebo, using a least squares mean, a model-based average that adjusts for differences in where people started.
Because two doses were each compared with placebo, the authors reported 97.5% confidence intervals instead of the usual 95%, a stricter bar that guards against false positives from running two comparisons.
What the Trial Found
Both schedules beat placebo on the primary outcome. The size of the benefit was very different between them.
On once-daily rimegepant, people lost about 1.8 more migraine days a month than people on placebo. On the every-other-day schedule, the extra benefit was about 0.6 days a month, and the upper end of its confidence interval sat just below zero. That clears the bar for statistical significance, but only by a small margin.
The study tested its key secondary outcomes in a fixed order, a method that stops testing at the first miss to avoid chance findings. Once-daily dosing cleared all five. Every-other-day dosing missed the very first one, so none of the later secondary outcomes for that schedule can be counted as confirmed. The abstract does not name each secondary outcome, so we have not listed them here.
| Group | People | Monthly migraine days vs placebo | Key secondary outcomes |
|---|---|---|---|
| Rimegepant (Nurtec ODT) 75 mg once daily | 229 | -1.8 (97.5% CI -2.35 to -1.19), P < 0.0001 | All 5 met |
| Rimegepant (Nurtec ODT) 75 mg every other day | 232 | -0.6 (97.5% CI -1.22 to -0.01), P = 0.022 | First one not met |
| Placebo once daily | 231 | Reference group | Reference group |
For a sense of scale, the once-daily difference is in the same range that placebo-controlled trials have reported for other oral preventives, including the daily gepant atogepant (Qulipta). Our summary of atogepant's prevention trials lays out those numbers by dose.
Side Effects
The authors report that both schedules were well tolerated and that most adverse events were mild or moderate. The published abstract does not break down which side effects were most common or how often they happened in each group, so we can't compare daily and every-other-day dosing on tolerability from the abstract alone.
Daily use over 12 weeks is the longest continuous daily exposure tested in this trial. It does not tell us about daily use over a year or more.
What This Means in Practice
If you take rimegepant every other day for prevention and you feel it helps only a little, this trial gives you something concrete to bring to your next visit: the daily schedule's placebo-adjusted drop in migraine days was about three times larger than the every-other-day schedule's, although the two were not compared directly.
Don't change your dose on your own. Daily dosing for prevention is not the schedule on the US label, insurance plans often cover a fixed number of tablets a month, and rimegepant should not be taken more than once in 24 hours. If you also use it to treat attacks, that has to be planned with your clinician so the doses don't stack.
Insurance is the practical hurdle. A daily schedule needs roughly twice as many tablets as every other day, and coverage limits are usually written around the approved schedule. Our guide to step therapy and prior authorization for migraine drugs explains how exception requests work.
This is Class I evidence that rimegepant 75 mg once daily outperforms placebo for episodic migraine prevention, with a placebo-adjusted reduction of 1.8 monthly migraine days. The every-other-day arm met its primary endpoint by a narrow margin and failed the first hierarchical secondary endpoint. The trial was not powered to compare the two schedules directly. Current AAN and AHS guidance on prevention is summarized in our prevention guideline overview.
Some people already use rimegepant both ways, as a preventive and for breakthrough attacks. Our earlier write-ups cover real-world results with every-other-day prevention and how consistently it works across repeated attacks.
What the Study Can't Tell Us
- No head-to-head comparison. The authors state plainly that the trial was not designed to compare once daily with every other day. Each schedule was tested only against placebo, so the gap between -1.8 and -0.6 is suggestive, not a formal finding.
- Episodic migraine only. Everyone had 4 to 14 attacks a month. The results do not apply to chronic migraine.
- Twelve weeks. The double-blind phase lasted 12 weeks, so longer-term benefit and safety of daily dosing remain open.
- Industry funding. Several authors are Pfizer employees, and Pfizer makes rimegepant. That is common for drug trials and does not change the results, but readers should know it.
The published abstract also does not report how many people in each group had their migraine days cut by half or more, or each group's raw drop from baseline, so those figures are not included here.
Key Takeaways
- In a 692-person, placebo-controlled trial, rimegepant (Nurtec ODT) 75 mg once daily cut about 1.8 more monthly migraine days than placebo over 12 weeks.
- The approved every-other-day schedule cut about 0.6 more days than placebo and missed its first key secondary outcome.
- Most side effects were mild or moderate on both schedules.
- The trial did not compare the two schedules directly, and it included only people with episodic migraine.
- Daily dosing for prevention is not the US labeled schedule, so any change belongs in a conversation with your clinician.
This article is for educational purposes only and does not replace medical advice, diagnosis, or treatment. Do not start, stop, or change the dose of any medication without talking with your physician or another qualified clinician. Individual responses to treatment vary.
References
- Goadsby PJ, Tassorelli C, Fountaine RJ, et al. Efficacy and safety of 2 rimegepant dosing regimens for the prevention of episodic migraine: a randomized controlled study. Neurology. 2026;107(12):e218773. doi:10.1212/WNL.0000000000218773
- Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet. 2021;397(10268):51-60. doi:10.1016/S0140-6736(20)32544-7


This article is for education and is not medical advice. Talk with your own clinician before starting, stopping or changing any treatment.

